Drug intelligence / Profile preview

Renshen Zhuye decoction

Development stage: Preclinical
Administration: Oral

Overview

Renshen Zhuye decoction (RZD) is a traditional Chinese medicine (TCM) formula primarily composed of Ginseng (Renshen) and Bamboo leaf (Zhuye). Historically utilized for the treatment of diabetes, RZD is currently being investigated for its potential to ameliorate high-fat diet-induced obesity and insulin resistance. Its mechanism of action involves the modulation of gut microbiota composition and function, which leads to improved intestinal barrier integrity (via increased expression of tight junction proteins such as Occludin) and reduced systemic and intestinal inflammation. These changes contribute to enhanced glucose tolerance, insulin sensitivity, and metabolic homeostasis in preclinical models.

Other names: Renshen-zhuye decoction

Beyond the preview

Go deeper on Renshen Zhuye decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renshen Zhuye decoction.

Explore the full profile